Lataa...
Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
BACKGROUND: Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer. Both ERBB2 (HER2) and ERBB3 (HER3) belong to the same family of receptor tyrosine kinases. Dimerization of these receptors leads to activation of cell...
Tallennettuna:
| Julkaisussa: | Exp Hematol Oncol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6114032/ https://ncbi.nlm.nih.gov/pubmed/30181930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0111-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|